Core Insights - Regentis Biomaterials Ltd. is expanding its U.S. clinical site network to enhance its infrastructure for ongoing and future clinical programs [1] - The company has surpassed 50% patient enrollment in its pivotal Phase III study of GelrinC® for knee cartilage repair [1] - GelrinC is positioned to transform the cartilage repair market with its off-the-shelf regenerative products [1] Company Developments - The expansion of clinical sites is expected to accelerate patient enrollment in the ongoing Phase III study [1] - The new sites will also support future clinical programs beyond the current study [1] Industry Impact - GelrinC is anticipated to significantly impact the cartilage repair market by providing innovative regenerative solutions [1]

Winter Park, Florida--(Newsfile Corp. - January 28, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its medical division Adia Med specializing in regenerative therapies, is proud to announce an upcoming documentary chronicling the recovery of professional wrestler Jeff Sciullo—known to fans as Elias in WWE and Elijah in TNA—from a tricep injury sustained in June 2025. The film will focus on his treatment with Adia Med's AdiaVita, a high-potency stem cell product delivering over 100 million umbilical cor ...

Core Viewpoint - Adia Nutrition Inc. has received notification from the SEC that its Form 10 registration statement will automatically become effective on February 3, 2026, marking a significant milestone in its transition to full SEC reporting status [1][2][4]. Group 1: SEC Registration and Reporting - The Form 10 was originally filed on December 5, 2025, and its effectiveness will enhance transparency for investors through regular audited financial disclosures, including annual reports on Form 10-K and quarterly reports on Form 10-Q [2][4]. - The notification from the SEC is seen as a major step forward for Adia Nutrition, as it will provide investors with increased confidence and transparency starting February 3 [3][4]. Group 2: Business Operations and Growth Strategy - Adia Nutrition focuses on delivering innovative healthcare solutions through its divisions, including Adia Med clinics that specialize in advanced stem cell therapies and Adia Labs that provide biologic products to healthcare providers [5][7]. - The company generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments, while also investing in aligned businesses like Cement Factory LLC [8]. Group 3: Future Prospects and Strategic Partnerships - The effectiveness of the Form 10 will trigger standard SEC reporting obligations, aligning Adia with best practices in public company disclosure and positioning it to meet eligibility requirements for potential listing on a national exchange [4]. - The company encourages clinic owners and healthcare practitioners to explore licensing the Adia Med name or integrating its regenerative therapies into their practices, indicating a focus on strategic partnerships to expand access to advanced stem cell solutions [6].

Winter Park, Florida--(Newsfile Corp. - January 15, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its medical division Adia Med specializing in advanced regenerative therapies, announces that Emmanuela Derisbrun, APRN, FNP-C, has transitioned from subcontractor to employed provider. This move supports rising patient volume and the launch of Adia Med's IRB-approved autism spectrum disorder regenerative study.Emmanuela Derisbrun, APRN, FNP-CTo view an enhanced version of this graphic, please visit:https ...

Core Insights - Regentis Biomaterials Ltd. has published long-term follow-up results from its Phase II clinical trial of GelrinC in the peer-reviewed journal Cartilage, marking a significant advancement in cartilage repair technology [1] - The study utilized the MOCART quantitative standard to measure cartilage regeneration, establishing GelrinC as a leader in long-term durable cartilage repair [1] - Two years post-treatment, the repaired cartilage demonstrated morphology very close to that of normal healthy cartilage, indicating the long-term durability and competitive superiority of GelrinC in the cartilage repair market [1] Company Developments - GelrinC is already approved in Europe and is currently undergoing a pivotal Phase III study with the U.S. FDA [1] - The data presented reinforces Regentis's position in the regenerative medicine sector, focusing on innovative tissue repair solutions [1]

Winter Park, Florida--(Newsfile Corp. - January 5, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine through its subsidiary Adia Med, today announced that its patent-pending clinical study targeting Autism Spectrum Disorder (ASD) has gone live on ClinicalTrials.gov, marking a significant advancement in the company's research pipeline.Clinical trial NCT07304440To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/279460_adi ...

Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced a year-end recap of its pivotal 2025 achievements. The company delivered remarkable financial performance, operational expansion, and strategic milestones, positioning itself for sustained growth and an anticipated Nasdaq uplisting."2025 has been a defining year of execution and momentum for Adia Nutrition," s ...

Core Insights - Organogenesis Holdings Inc. has successfully completed a Type-B meeting with the FDA, confirming the initiation of a rolling Biologics License Application (BLA) for its product ReNu, expected to be submitted by the end of December 2025 [2][3] Company Overview - Organogenesis Holdings Inc. is a leading regenerative medicine company focused on developing, manufacturing, and commercializing solutions for advanced wound care and surgical and sports medicine markets [5] - The company offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care [5] Product Details - ReNu is a cryopreserved amniotic suspension allograft designed for managing symptomatic knee osteoarthritis, consisting of amniotic fluid cells and micronized amniotic membrane [4] - The product has been studied in three large randomized controlled trials (RCTs) involving over 1,300 patients and received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for knee osteoarthritis in 2021 [4] Market Context - Knee osteoarthritis (OA) affects an estimated 31.1 million Americans, projected to increase to 34.4 million by 2027, making it one of the most common causes of disability and poor quality of life [3]

Winter Park, Florida--(Newsfile Corp. - December 15, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its Adia Med subsidiary, today announced that the independent Institutional Review Board (IRB) BeyondBound has approved the company's patent-pending clinical study protocol focused on Autism Spectrum Disorder (ASD).IRB Approval EmailTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/278050_adia_irb_approved_screenshot.jp ...

Core Insights - Regenerative Medical Technologies Group, Inc. has launched its CELLGENIC Peptide Pen product line, enhancing its position in the regenerative medicine market [1] - The introduction of this product line aims to simplify and modernize peptide therapy, aligning with trends in longevity medicine [1] - The new product line is expected to generate additional revenue through the company's established physician distribution network across over 30 countries [1] Company Overview - Regenerative Medical Technologies Group, Inc. is recognized as a global leader in regenerative medicine solutions [1] - The company is actively expanding its product offerings to meet the growing demand for innovative medical therapies [1] Market Impact - The launch of the CELLGENIC Peptide Pen is positioned to create new revenue streams, indicating a strategic move to capitalize on the expanding market for peptide therapies [1] - The product line's introduction during the ISSCA Global Summit highlights the company's commitment to innovation and leadership in the field [1]